Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

<p>Whole-exome sequencing and RNA sequencing analyses of tumor tissue samples at pre-and post-treatment</p>

Salvato in:

Dettagli Bibliografici
Autore principale:	Takafumi Koyama (15035714) (author)
Altri autori:	Toshio Shimizu (15050147) (author), Yuki Kojima (14182957) (author), Kazuki Sudo (16374908) (author), Hitomi Sumiyoshi Okuma (16540569) (author), Tatsunori Shimoi (16540572) (author), Hitoshi Ichikawa (16540575) (author), Shinji Kohsaka (14957594) (author), Ryo Sadachi (16540578) (author), Akihiro Hirakawa (16540581) (author), Akihiko Yoshida (16540584) (author), Reiko Makihara Ando (16540587) (author), Toshihide Ueno (14946328) (author), Mitsuru Yanagaki (15093837) (author), Naoko Matsui (16540590) (author), Kenichi Nakamura (16540593) (author), Noboru Yamamoto (15013614) (author), Kan Yonemori (15033972) (author)
Pubblicazione:	2025
Soggetti:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Methods and Technology Biomarkers Small molecule biomarkers Clinical Trial Results Phase II clinical trials Liquid Biopsy Sarcomas Soft-tissue sarcoma
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
di: Takafumi Koyama (15035714)
Pubblicazione: (2025)

Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
di: Takafumi Koyama (15035714)
Pubblicazione: (2025)

Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
di: Takafumi Koyama (15035714)
Pubblicazione: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
di: Nam Q. Bui (14958210)
Pubblicazione: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
di: Srivandana Akshintala (16610490)
Pubblicazione: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
di: Srivandana Akshintala (16610490)
Pubblicazione: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
di: Tom Wei-Wu Chen (15053003)
Pubblicazione: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
di: Tom Wei-Wu Chen (15053003)
Pubblicazione: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
di: Tom Wei-Wu Chen (15053003)
Pubblicazione: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
di: Tom Wei-Wu Chen (15053003)
Pubblicazione: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
di: Tom Wei-Wu Chen (15053003)
Pubblicazione: (2025)

Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
di: Johanna Falkenhorst (15039017)
Pubblicazione: (2025)

Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
di: Johanna Falkenhorst (15039017)
Pubblicazione: (2025)

Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
di: Johanna Falkenhorst (15039017)
Pubblicazione: (2025)

Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
di: Johanna Falkenhorst (15039017)
Pubblicazione: (2025)

Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
di: John A. Ligon (15024477)
Pubblicazione: (2025)

Supplemental Data 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
di: Elisabeth Ashton (22247398)
Pubblicazione: (2025)

Supplemental Data 2 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
di: Elisabeth Ashton (22247398)
Pubblicazione: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
di: Yan Zhou (15053225)
Pubblicazione: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
di: Kristoffer Staal Rohrberg (15009138)
Pubblicazione: (2025)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
di: Roberto Carmagnani Pestana (15294422)
Pubblicazione: (2025)

Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Figure 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Figure 3 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Figure 4 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Table 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Table 2 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
di: Christian Rolfo (17314293)
Pubblicazione: (2025)

Figure 1 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)
di: Dario Callegaro (15054685)
Pubblicazione: (2025)

Figure 2 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)
di: Dario Callegaro (15054685)
Pubblicazione: (2025)

Figure 3 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)
di: Dario Callegaro (15054685)
Pubblicazione: (2025)

Table 1 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)
di: Dario Callegaro (15054685)
Pubblicazione: (2025)

Table 2 from CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)
di: Dario Callegaro (15054685)
Pubblicazione: (2025)